potential €6.45-billion offer significantly undervalued the Spanish drugmaker’s prospects and long-term potential.
Grifols said its board would meet later on Tuesday to consider the potential offer, but that, given the valuation, it would not be in a position to recommend that shareholders accept it.
لقد قمنا بتلخيص هذا الخبر حتى تتمكن من قراءته بسرعة. إذا كنت مهتمًا بالأخبار، يمكنك قراءة النص الكامل هنا. اقرأ أكثر: